ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models.
Hanson A, Elpek K, Duong E, Shallberg L, Fan M, Johnson C, Wallace M, Mabry GR, Sazinsky S, Pepper L, Shu CJ, Sathyanarayanan S, Zuerndorfer S, Simpson T, Gostissa M, Briskin M, Law D, Michaelson J, Harvey CJ.
Hanson A, et al.
PLoS One. 2020 Sep 24;15(9):e0239595. doi: 10.1371/journal.pone.0239595. eCollection 2020.
PLoS One. 2020.
PMID: 32970735
Free PMC article.